MedTrace Logo

Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19

NCT04634903 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2452

Last updated 2021-05-25

Study results available
· View outcomes & findings →

Summary

Most mental health problems emerge by age 14, often leading to chronic impairments and adverse impacts for individuals, families, and societies. Any action-focused path to reducing the need-to-access gap will require moving beyond the dominant settings, formats, and systems that have constrained intervention delivery to date. In a fully-online trial, youths ages 13-16 will be randomized to 1 of 3 self-administered single-session interventions (SSIs): a behavioral activation SSI, targeting behavioral MD symptoms; an SSI teaching growth mindset, targeting cognitive MD symptoms; or a control SSI. The investigators will test each SSI's relative benefits, versus the control, on depressive symptoms and proximal outcomes such as hopelessness. Results will reveal whether SSIs that were designed to address behavioral versus cognitive symptoms differentially benefit adolescents with elevated depressive symptoms.

Conditions

Interventions

BEHAVIORAL

Supportive Therapy SSI

Online, 30-minute self-administered program for youth

BEHAVIORAL

Behavioral Activation SSI

Online, 30-minute self-administered program for youth

BEHAVIORAL

Growth Mindset SSI

Online, 30-minute self-administered program for youth

Sponsors & Collaborators

Principal Investigators

  • Jessica L Schleider, PhD · Stony Brook University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-19
Primary Completion
2021-03-15
Completion
2021-03-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04634903 on ClinicalTrials.gov